View Clinical Trial (Medical Research Study)
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
| City: |
|
Chicago |
| State: |
|
Illinois |
| Zip Code: |
|
60637 |
| Conditions: |
|
Bone Metastases - Castrate-resistant Prostate Cancer - Recurrent Prostate Cancer - Stage IV Prostate Cancer |
| Purpose: |
|
This study is being done to help researchers understand more about prostate cancer that has
spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to
better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone
disease. The other purposes of the study are to better understand the effect of XL184 on
prostate cancer progression, bone pain, and on any cancer cells that patients may have
circulating within the blood (called circulating tumor cells)
|
| Study Summary: |
|
PRIMARY OBJECTIVES:
I. To determine effect of XL184 on the functional MRI metrics Ktrans and apparent diffusion
coefficient (ADC) within castrate resistant prostate cancer bone metastases.
SECONDARY OBJECTIVES:
I. To quantify progression free survival in men with castrate resistant prostate cancer
(CRPC) treated with XL184 according to Prostate Cancer Working Group criteria.
II. To correlate and changes in MRI based functional metrics with bone scan, prostate
specific antigen (PSA), Response Evaluation Criteria in Solid Tumors (RECIST) response
criteria, circulating tumor cells (CTC) number and with changes in pain.
III. To explore c-MET, phospho-c-MET staining on circulating tumor cells as a predictive
biomarker for response and duration of response to XL-184.
OUTLINE:
Patients receive cabozantinib orally (PO) once daily (QD). Treatment continues in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
|
| Criteria: |
|
Inclusion Criteria:
- Histologically or cytologically confirmed prostate cancer with progressive disease
- Evidence of castration resistance defined as disease progression despite a
testosterone level < 50ng/dL (or surgical castration)
- Evidence of metastatic disease to the bones within the lumbar spine, sacrum, or
pelvic bones that is identifiable on screening pelvic MRI
- If patient has had prior pelvis radiation therapy (RT), then bone metastases must be
out of radiated port (e.g. lumbar or sacral spine)
- Any prior therapy for castrate disease acceptable other than prior XL184 with a
minimum washout of 28 days for any other anticancer therapy
- Patients with castrate resistant disease post antiandrogen therapy/withdrawal must
meet at least one of the following criteria:
- Have not received docetaxel chemotherapy
- Have received docetaxel chemotherapy but received less then 225mg/m2 cumulative
dose
- Have documented liver metastases
- Have no pain or pain that does not require a long acting (SR) narcotic
- Have received mitoxantrone chemotherapy in the past for CRPC
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study
- Patients who are receiving any other investigational agents
- Prior treatment with other vascular endothelial growth factor (VEGF) or c-MET
targeted therapies
- History of hematemesis or hemoptysis
- The subject has uncontrolled or significant intercurrent illness
- The patient requires concomitant treatment, in therapeutic doses, with anticoagulants
|
| NCT ID: |
|
NCT01599793 |
| Primary Contact: |
|
Principal Investigator
Russell Szmulewitz
University of Chicago Comprehensive Cancer Center
Elia Martinez, RN
Phone: 773-702-3623
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Chicago, Illinois 60637
United States
Russell Z. Szmulewitz
Phone: 773-702-7609
Email: rszmulew@medicine.bsd.uchicago.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|